Nontraumatic corneal ulceration leading to perforation is the result of many different noninfectious and infectious destructive conditions of the cornea. Because corneal perforation has a high ocular morbidity, prompt recognition and treatment may preserve useful vision. 1 Failure to diagnose and treat a perforation early can lead to further corneal damage, cataract formation, glaucoma development, endophthalmitis, and loss of the eye. Available treatments for the management of nontraumatic corneal perforation include medical treatment, 2, 3 tissue adhesive, 4,5 lamellar keratoplasty, and penetrating keratoplasty (PK). 1, 3, 6 
PATIENTS AND METHODS
The records of patients with the diagnosis of corneal perforation without a history of eye trauma or corneal surgery who were treated on the Cornea Service at the Wills Eye Hospital from February 1992 through January 1999 with at least three months follow-up, were reviewed retrospectively. If the patients had repeated episodes of corneal perforations in the same eye, only the first corneal perforation was analyzed. Diagnoses were based on clinical history, biomicroscopic examination, tear-film studies, as well as smears and cultures.
The data analyzed included patient age, sex, best corrected visual acuity (BCVA) at presentation, final BCVA, size, location and shape of corneal perforation, ocular history, and medical treatment. Treatment and visual outcome also were analyzed. Visual outcomes as they related to varying diagnoses were analyzed by examining the covariance of final visual acuity as the dependent variable and the baseline visual acuity as the covariate, with treatment as the grouping variable. The Wilcoxon rank sum test for independent groups was used to analyze the correlation between age and rheumatoid arthritis (RA).
Histoacryl (B. Braun Melsungen AG D-34209, Melsungen, Germany) was used as a tissue adhesive. It was applied under topical proparacaine anesthesia after the insertion of a lid speculum. The surrounding epithelium was scraped, and the area of the perforation was dried with a cellulose sponge. A small amount of tissue adhesive was applied to the perforation and ulcer, reaching the surrounding normal basement membrane tissue. A flat, low-watercontent bandage soft contact lens was placed before removal of the lid speculum.
In this study, we treated corneal perforations with tissue adhesive when the perforations were <1.0 mm in diameter at the level of Descemet's membrane and were concave. If active infection was present, it was treated for 48-72 hours before tissue adhesive was applied. We managed corneal perforations medically when they were small (Յ1.0 mm in diameter), without iris prolapse, and could not be treated with tissue adhesive because of ectatic configuration, or when associated with a poor visual prognosis for PK. Medical treatments used to manage perforations included patching and/or shielding, topical and systemic hypotensive agents to diminish the flow of aqueous humor, topical and systemic antibiotics (all received topical and systemic antibiotics), and antifungal agents (in cases of fungal keratitis).
A PK was used to treat large corneal perforations (>1.0 mm in diameter) with iris prolapse, with a flat or very shallow anterior chambers for >48 hours, and with good visual potential that failed to respond to medical treatment or tissue adhesive. The corneal button was removed, and a 0.5 mm oversized donor cornea was sutured using a 10-0 nylon interrupted suture technique, after peripheral iridectomies were performed. Occasionally, a lamellar keratoplasty was performed using full-thickness corneal donor tissue but leaving some host tissue peripheral to the perforation in the recipient bed. We avoided conjunctival flaps in patients with corneal perforations. Generally, the size of the perforation and visual potential, but not the location (peripheral vs. central), determined the management. 
RESULTS
A total of 40 eyes of 37 patients were treated for nontraumatic corneal perforations over a seven-year period (Table 1) . There were 14 men (38%) and 23 women (62%). The ages ranged from 25 to 91 years, with a mean of 63.4 years (Fig. 1) . The follow-up period ranged from 3 to 84 months (mean, 24.5 months).
At presentation, 35 eyes (87.5%) had a BCVA of Յ20/200 (Table 2) . One patient had Down's syndrome, and visual acuity could not be tested accurately. The location of the perforation was central in 22 eyes and peripheral in 18 eyes.
The most common cause of perforation was keratoconjunctivitis sicca (KCS) in 12 eyes of nine patients. Other causes included bacterial keratitis (six eyes), exposure keratopathy (five eyes), HSV keratitis (four eyes), fungal keratitis (three eyes), ocular pemphigoid (two eyes), and rosacea (two eyes) ( Table 3 ). Cultures or scrapings (Table  4) confirmed the presence of bacterial or fungal infections.
The underlying medical diseases included secondary Sjögren's syndrome related to RA (five patients), thyroid disease (two patients with exposure keratopathy and three on thyroid medication only), and rosacea (three patients), as well as primary Sjögren's Syndrome (one patient). Nine perforations were secondary to infection (six bacterial and three fungal). Bacterial isolates included Staphylococcus, Streptococcus, and Pseudomonas. Fungal isolates included both yeasts and filamentous organisms (Table 4) . There was no statistically significant correlation between age and RA (Wilcoxon rank sum test for independent groups, p ‫ס‬ 0.45). Furthermore, we found no significant relationship between the average visual improvement in perforations associated with RA versus those related to another diagnosis after adjustment for different treatment modalities.
Tissue adhesive was applied in 15 eyes. Of the 15 eyes treated with tissue adhesive, 8 had to be reglued for recurrent leaks or glue dislodgment within several days and 1 eventually needed PK for refractory leaking. Thirteen eyes were treated by medical treatment. The wound sealing time for medically treated leaks ranged 
KCS, keratoconjunctivitis sicca; HSV, herpes simples virus; OCP, ocular cicatricial pemphigoid; HZV, herpes zoster virus. from 2 to 30 days, with a mean of 8.8 days. Nine eyes developed repeated perforations. These subsequent perforations were excluded from further evaluation. PK was used when the perforation could not be glued and the visual potential was good. PK was performed in eight eyes. Of these eight, four eyes (50%) improved in BCVA and four eyes achieved a clear graft. Lamellar keratoplasty was used in one eye. In cases of RA, medical management included systemic immunosuppression in some patients. Two blind painful eyes were eviscerated, and one blind painful eye was enucleated after successful treatment of the perforations (Table 5) .
The initial and final BCVA demonstrated a statistically significant direct relationship for all therapies combined. Visual acuity improved Ն2 Snellen lines in 3 of 8 eyes (37.5%) treated with PK, in 5 of 14 eyes (35.7%) of those treated with tissue adhesive, and in 1 of 12 eyes (8.3%) of those treated medically (Table 6 ). The final BCVA after the treatment of 15 (37.5%) of nontraumatic corneal perforations was improved (Fig. 2) .
DISCUSSION
In this study, the etiologies of nontraumatic corneal perforations included sterile corneal ulcers (23 patients, 57.5%) that are most commonly associated with a) KCS and RA, b) exposure keratopathy, c) neurotrophic keratopathy (HSV in 4 patients and herpes zoster virus in 1 patient), as well as bacterial and fungal corneal ulcers (9 patients, 22.5%). KCS is the most common cause of nontraumatic corneal perforation in this study (12 30%). Women were more frequently affected by this problem than men (seven of nine patients, 77.8%). We found RA to be the most common underlying condition associated with KCS-related corneal perforation (five of nine patients [55.6%], four women and one man). The ages ranged from 49 to 73 years, with a mean of 65.4 years. RA is the most common collagen vascular disorder that involves the ocular surface. 7 Women are primarily affected. Of RA patients, 24-31% have Sjögren's syndrome. 8 When a patient presents to an ophthalmologist with a corneal perforation associated with KCS, advanced RA is usually evident. Keratolysis is the mechanism of corneal perforation in these patients. 9 In most cases, severe aqueous tear deficiency is found. The superficial layers of the cornea begin to ulcerate and a descemetocele may develop and be followed by perforation. 10 Dry eyes should be treated aggressively in RA patients. Frequent lubrication, punctal occlusion, and tarsorrhaphy may be useful in promoting reepithelialization. Immunosuppressive agents may be useful in alleviating the immunologic process responsible for the corneal melting.
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This study demonstrated a statistically significant direct correlation between presenting and final BCVA for the aggregate of all treatment types (R 2 ‫ס‬ 0.38, p ‫ס‬ 0.0001, Fig. 2 ). That is, the better the presenting vision, the better the final vision after therapy. We found no statistically significant correlation between treatment modality and final visual acuity after adjusting for varying presenting visual acuity ( Figs. 2A-C) . However, biases existed in this study. The underlying disease and visual potential did influence the treatment modality. Consequently, the varying presenting visual acuity, associated with different diagnoses, confounded the outcome of therapy.
The objective in treating a patient with a corneal perforation is to restore the integrity of the globe and useful vision. This goal may require a sequence of procedures. The goals of initial intervention are to close the perforation and restore the integrity of the globe. This should be done as rapidly as possible to minimize peripheral anterior synechiae and risk of cataract formation and intraocular infection.
Tissue adhesive works well when the corneal perforation is Յ1.0 mm in diameter at the level of Descemet's membrane, away from limbus, and is concave in shape with a crater for the tissue adhesive. In many cases, adhesive is sufficient treatment that promotes healing and scarring while obviating the need for further surgery. Tissue adhesive is left in place for several months until it dislodges spontaneously. Adhesive has been shown to be bacteriostatic to gram-positive (but not to gram-negative) organisms, especially during polymerization. 12 Tissue adhesive has also been shown to slow stromal-melting, 13 possibly by preventing invasion by tear-borne inflammatory cells. Adhesive supports the stroma tectonically through vascularization and fibroplasia.
14 Tissue adhesive is not an option for large corneal perforations (>2 mm in diameter) or in anterior bulging corneal perforations.
In our experience, the application of tissue adhesive was often sufficient to promote adequate healing without surgery. Many surgeons recommend keratoplasty following tissue adhesive applications. 15 In this study, tissue adhesive was applied in 15 eyes; 14 eyes (93.3%) achieved tectonic stability and 6 (42.8%) improved in final BCVA. Only 1 of 15 eyes required a PK because the perforation was not sealed by tissue adhesive.
Medical treatments can be effective in the management of small perforations (Յ1 mm in diameter) without iris prolapse. However, in these cases, the time to resolution of the leak may be prolonged. Medical therapy was used when application of tissue adhesive was not feasible because of an ectatic perforation and/or active infection. In pinpoint or small perforations, patching may be effective if stromal swelling seals the perforation and there is no infection. We used topical or systemic hypotensive agents to diminish the flow of aqueous humor and to promote closure of the tissue defect. 16 Using medical treatment, we were able to achieve tectonic stability in 13 eyes (32.5%). Final BCVA was improved in 5 of 12 eyes (41.6%). Visual acuity was not measured in one case because the patient had Down's syndrome. If there was no contraindication to medical treatment, we used this treatment for infectious corneal perforation first because the outcome of surgical treatment is suboptimal when the infection is uncontrolled. Perforations are also frequently ectatic in this setting.
Larger central perforations (>1 mm in diameter) should be treated with PK as initial therapy if the visual potential is good. We believe that patients with microbial keratitis should be treated aggressively with topical fortified antibiotics for a period of 24-48 hours before PK. Corneal transplantation in a perforated cornea is technically difficult, and the possibility of injuring other anterior segment structures is always present. Although the anatomic success in our keratoplasty series was high, only four of eight (50%) achieved a clear graft. The success of PK in the treatment of corneal perforation depends on the timing of surgery and the cause of the perforation. Ideally, PK is deferred until the eye is quiet. However, this is frequently not possible when the perforation cannot be glued or does not respond to medical therapy. If the visual acuity after tissue adhesive was poor because of scarring, a PK could be performed at a later date when the inflammation had subsided. However, in our experience, this was usually not necessary. Corneal transplantation was not recommended in patients with perforations successfully managed medically or with tissue adhesive because of the poor prognosis associated with severe ocular surface disease and, in some cases, preexisting posterior segment pathology.
Finally, we can decrease the incidence of nontraumatic corneal perforation by early detection and aggressive treatment of ocular surface conditions including KCS, HSV, and herpes zoster virus neurotrophic keratopathy, exposure keratopathy, and rosacea. In addition, these underlying diseases must be treated after perforation to decrease the likelihood of recurrent problems and to improve the outcome of PK.
